Avacta Therapeutics posted a £38.6 million loss for 2025 amid strategic focus on its proprietary pre|CISION® cancer drug platform. The company progressed two clinical-stage programs, AVA6000 and AVA6103, showing promising safety and efficacy data, especially in salivary gland cancer. It strengthened its financial position by raising £10 million in March 2026, extending its cash runway into early 2027. Avacta expects initial clinical data from AVA6103 in late 2026 and plans further development and potential partnerships to advance its oncology pipeline.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
AI Financial Corp. disclosed that its $706 million WLFI token treasury is locked and unavailable for sale, raising serious liquidity and going concern issues. The company acquired 7.28 billion WLFI tokens in a $1.5 billion deal but the token value ha...
Oaktree Specialty Lending (OCSL) missed Q2 expectations due to a significant drop in net investment income, leading to a 25% cut in its regular dividend. Despite paying a supplemental dividend that reduced the effective cut to 15%, the company faces ...
Stellantis announced a new project to produce a small, affordable electric car, called the E-Car, starting in 2028 at its Pomigliano d’Arco plant in Italy. The E-Car aims to revive the small car segment in Europe with a focus on European design, affo...
XRP is seeing a resurgence in retail trading activity, with CryptoQuant data showing increased trading frequency among smaller traders, often a sign of upcoming major price swings. The token recently rose above $1.5, and analysts note its current pri...
